



OPAL BIOSCIENCES LIMITED

ABN 97 605 631 963

Level 4,

100 Albert Road,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.opalbiosciences.com

Opal Biosciences Announces Addition to its Board of Directors

Melbourne, 28 August 2018: The Directors of Opal BioSciences Limited (“Opal”, or the “Company”) are pleased to announce an addition to its Board of Directors.

Mr Peter Snowball has joined the Opal Biosciences board as a non-executive director. Peter’s successful career in the financial markets started at Barclays Bank and then the London Futures Exchange. After emigrating to Australia in 1971 he traded on the Sydney Wool Futures Exchange for global clients. Then back in London for a short time Peter became a senior broker at Shearson Lehmann Brothers with his own client base of professional traders, trading mainly financial futures in Chicago.

Later in Australia Peter set up a financial futures broking desk at Merrill Lynch in Sydney and subsequently at Firmat Australia, broking interest rate futures into Singapore and Chicago.

Peter moved to J B Were in 1994 where he switched to broking equities for retail clients and within five years became one of the biggest business writers in the Sydney office and in the Company. After a short time supporting the Philanthropic Services team, Peter left J B Were in 2014 and moved to roles with smaller private companies assisting in company turn-arounds and corporate transactions. Most recently Peter was chairman of Manna from Heaven Pty Ltd and is the current chairman of Philip Shaw Wines Pty Ltd.

The Opal directors are delighted to welcome Peter, who as an investor in Australian and overseas biotechnology companies, brings a complementary skillset and investor’s and financial markets perspective to the Opal board. Peter is a shareholder in both BioDiem Ltd, Opal’s parent company as well as one of the foundation shareholders in Opal itself.

- ENDS -

For further information contact

Julie Phillips

Managing Director

Opal Biosciences Limited

Phone +61 3 9692 7240

Email jphillips@opalbiosciences.com

Twitter @opalbiosciences

About Opal Biosciences Ltd (www.opalbiosciences.com)

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives.

In laboratory testing a BDM-I gel (Opal-T) has shown antimicrobial activity against **methicillin-resistant Staph aureus** (Golden Staph; MRSA). This bacterium is responsible for mild to severe infections, from boils and abscesses to life threatening meningitis, bone or lung infections. Antibiotic-resistant infections can be difficult to treat.

Opal-T gel has also shown activity against **Neisseria gonorrhoea**, a bacterium responsible for causing the sexually-transmitted disease, gonorrhoea. Rising reports of antibiotic resistance to gonorrhoea are concerning health authorities worldwide.

Opal is currently seeking funding to support the next stage of development of its products including Opal-I, an injectable product.